Entero Therapeutics (NASDAQ:ENTO) Stock Price Up 0.2% Following Analyst Upgrade

Entero Therapeutics, Inc. (NASDAQ:ENTO)’s stock price shot up 0.2% during trading on Friday after Wall Street Zen upgraded the stock to a hold rating. The stock traded as high as $4.44 and last traded at $4.35. 115,506 shares traded hands during trading, a decline of 69% from the average session volume of 371,240 shares. The stock had previously closed at $4.34.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Entero Therapeutics in a research note on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Entero Therapeutics has an average rating of “Sell”.

Entero Therapeutics Price Performance

The business’s fifty day simple moving average is $2.77 and its two-hundred day simple moving average is $1.83.

Entero Therapeutics (NASDAQ:ENTO) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.42) earnings per share for the quarter.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.